Regeneron Settles Its Sanofi Lawsuit, Then Adds Four Antibodies To The Alliance For $1.0 Billion Up Front
The drugmaker could collect up to $7.0 billion more in milestones, and profits on the new products will be split equally.
Regeneron ended its lawsuit against Sanofi on October 1 and then widened their antibody alliance in October, taking a $1.0 billion up-front payment and the right to up to $7.0 billion more in milestones, according to its quarterly report filed Friday.
Four antibodies, $8.0 billion on paper
Regeneron, the biotech behind Dupixent, EYLEA HD and Libtayo, amended the collaboration to add four long-acting antibodies it invented. They target IL-13, IL-4, IL-4 receptor alpha, and both IL-4 and IL-13 in a bispecific design.
The $1.0 billion has already been received but will be booked as collaboration revenue in the fourth quarter, so it sits outside the third quarter's $5,115.8 million of revenue. The further $7.0 billion depends on development, regulatory and sales milestones. The two companies will split worldwide profits on the new products down the middle, and bear agreed development costs equally.
Only one candidate, REGN20423, the IL-13 antibody, is in Phase 1 testing. The other three are expected to enter clinical studies in 2027.
Regeneron also gets an option, asset by asset after certain ongoing trials, to bring in Sanofi's lunsekimig, a Phase 2/3 bispecific targeting TSLP and IL-13, and another early Sanofi candidate. If it exercises, it reimburses Sanofi for certain development costs.
A lawsuit closed, a partner deepened
The prior quarter's filing described Regeneron's suit against Sanofi as ongoing. Regeneron had sued in November 2024. The new report says the parties signed a settlement on October 1 and the case was dismissed.
Sanofi is the larger relationship. Its collaboration revenue was $2,724.0 million in the third quarter, against $1,617.0 million a year earlier, as Regeneron's profit share rose to $2,574.9 million. The company said the Sanofi development balance, a debt repaid out of that profit share, was fully repaid as of June 30, and it no longer reduced revenue this quarter. The filing's risk factors now say Regeneron expects to keep relying on Sanofi for the foreseeable future, including for the new candidates.
Total third-quarter revenue rose to $5,115.8 million from $3,754.3 million a year earlier, and net income to $1,948.7 million from $1,460.0 million, the filing shows.
Legal calendar and the EYLEA fight
Regeneron also reported settling with Sandoz outside the United States, Australia and Canada on October 9, and with Sam Chun Dang on August 12, over biosimilar versions of the 2 mg EYLEA.
Two dated tests are next. A claim construction hearing in the Amgen patent case is scheduled for December 1, and oral argument before the Patent Trial and Appeal Board on a challenge to the EYLEA HD '036 patent is set for December 4.
Regeneron said it expects an FDA decision on cemdisiran in generalized myasthenia gravis in November, and its next dividend of $0.94 per share is payable December 3.
Sources
- 10-Q Filing — Regeneron (REGN) — SEC EDGAR
- 10-Q Filing — Regeneron (REGN), Q2 FY2026 filed 2026-07-30 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, exhibit991q32026.htm) — Regeneron, filed 2026-10-30 — SEC EDGAR
- Regeneron: Q3 Earnings Snapshot — Associated Press
- Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo Finance — Yahoo Finance
- Regeneron Pharmaceuticals Non-GAAP EPS of $20.07 beats by $3.82, revenue of $5.1B beats by $540M (NASDAQ:REGN) | Seeking Alpha — seekingalpha.com
- Missed Regeneron Pharmaceuticals' Rally? Here Is The Bull Case — Yahoo Finance
- Regeneron Pharmaceuticals (REGN) Posts Nearly Four Years Of Survival Benefit Data For Libtayo — Yahoo Finance
More on Regeneron Pharmaceuticals
- Regeneron Revenue Climbs 36% To $5.1 Billion As Sanofi Profit Share Surges, Plus A $1 Billion Up-Front Deal
- Sanofi Pays Regeneron $1.0 Billion Upfront For Four Antibodies, With Up To $7.0 Billion More In Milestones
- Regeneron Locks Co-Founders Into A Decade Of Performance Targets — No New Equity Until 2036